Novo oo faaido badan heshay sanadka 2012

Guusha shirkadda Novo Nordisk ayaa kor u sii socota, iyadoo heshay faaidooyin ka badan intii sannadkii hore.

Waxa weli cirka isku sii shareeraya guusha shirkadda Novo Nordisk ee la xidhiidha iibka dawooyinka insuliinta. Iibka iyo faaidaduba samada ayay marayaan.

Waa 'shaqadii lagu yiqiin' shirkadda Novo Nordisk.

Shirkadda dawooyinka ee deenishka ayaa hore u socota, sannadka 2012na kama duwanayn horumarka kuwii hore.

Boqolkiiba 18 dhinaca kobcitaanka ah
Shirkadda Novo Nordisk ayaa sannadka 2012 heshay faaidadii ugu badnayd oo dhan 27,8 bilyan koron cashuurta ka hor. Sannadkii 2011 waxa faaidadeedu ahayd 21,9 bilyan koron - sidaas awgeed xarriijinya gunta waxa kor looga kacay boqolkiiba 18.

IIbka ayaa diirranaa. Sannadkii hore iibku wuxu dhamaa 78 bilyan oo koron - marka loo eego sannadkii 2011 wuxu kor u kacay boqolkiiba 18.

Mana jiraan waxyaabo caddaynaya, in isbeddelo ku iman doonaan sannadkanna horukaca shirkadda Novo.

Faaido xuduudda sixirka ah
Saamilayda shirkadda Novo Nordisk ayaa kor maray xuduudda sixirka, oo ku kacday tiro ka badan 1000 koron 23kii janaweri ee sannadkan. Qiimaha sayladda ee shirkadduna wuxu haahaabanayaa 560 bilyan oo koron.

Teeda kale insuliinta shaqaysa muddada dheer,Tresiba, iyo insuliinta iskudhafka ah ee Ryzodeg ayaa sannadkii hore laga ansixiyay Yurub iyo Japan - haddana waxa la sugayaa in Maraykanku ansixiyo. Waana alaabooyinka ka qaybqaadab doona diilinta gunta.

Shirkadda Novo Nordisk ayaa sannadka 2013 filaysa korukac dhan boqolkiiba 8-10, sida shirkaddu ku warrantay.